Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q2 Revenues Flat

NEW YORK (GenomeWeb News) – Interleukin Genetics said after the close of the market on Tuesday that its revenues for the second quarter were essentially flat compared to the year-ago period.

The Waltham, Mass.-based genetic test developer said that during the three months ended June 30, it brought in revenues of $799,435, compared to $796,865 for Q2 a year ago. Genetic testing service revenue dipped slightly to $777,549 from $779,116 while other revenues increased to $21,886 from $17,749.

The company's R&D expenses decreased 12 percent to $317,440 from $359,799 a year ago, while SG&A spending was down 8 percent year over year to $1.2 million from $1.3 million.

Interleukin's net loss for the quarter was flat at $1.2 million, or $.03 per share, the same as in Q2 2011.

The company finished the second quarter with $3.8 million in cash and cash equivalents. Last month, Interleukin raised $3 million in a private placement. It said today that it has the financial resources to keep its operations running through at least Nov. 30. If the due date for a $1.3 million loan secured in April is extended beyond Nov. 30, its finances will be sufficient to maintain operations through Jan. 31, 2013, it added.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more